Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma Initiates Combined Phase I/II Clinical trial — NMD Pharma
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma - PIR International
Other news — NMD Pharma
Other news — NMD Pharma
NMD Pharma Raises €35 Million in a new Financing — NMD Pharma
NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma - PIR International
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Management team — NMD Pharma
privilégium Vyrobený z najmenej nmd pharma thomas hilm urýchliť repertoár diéta
Other news — NMD Pharma
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
NMD Pharma expands its US presence — NMD Pharma
Other news — NMD Pharma
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
privilégium Vyrobený z najmenej nmd pharma thomas hilm urýchliť repertoár diéta
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire
